Dr Neil H. Bander, Director of Urological Oncology Research at Weill Cornell Medical College from where the anti-PSMA antibody was licensed, said: 'We have direct experience with virtually every antibody-drug conjugate platform currently available; none have produced the level of efficacy we have noticed with ADC Therapeutics' PBD warheads - in vivo efficacy data from their PSMA-targeted ADC drug candidate are truly interesting, and we are thrilled to see this potentially breakthrough therapy translated right into a clinic plan as soon as possible.' Dr. Peter B. Corr, Chairman of ADC Controlling and Therapeutics General Partner of Auven Therapeutics, said: 'Having the technology platform to build up novel ADCs against essential tumor targets and transform health care outcomes for individuals is a critical part of what we are building at ADC Therapeutics.With the brand new software, a huge selection of 3-D blocks of the mind are scanned one at a time with a two-photon microscope then, and scientists can watch the scans immediately as opposed to looking forward to them to download. With the help of a researcher, the software then can easier and quickly assemble the blocks into one complete picture of a region of the mind and create a 3-D model that allows the scientist to view areas and angles that couldn't be observed as easily with 2-D images. In this way, researchers can map out the individual neurons and their lengthy tails, known as axons. It really unleashes a different level of understanding of the info itself - - having the ability to appear at something completely in 3-D also to rotate and look at in front and in back again, Pascucci said.